Dentsply Sirona (XRAY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$10.72-2.46%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Dentsply Sirona aims to return to growth with a $3.5B-$3.6B sales target for 2026. The company has stable profit guidance of $1.40-$1.50 EPS. New partnerships and a CFO hire support execution. The stock trades cheap at 8.5 PE versus peers near 30.
Revenue growth is nearly flat, with Q1 up only 0.1% year-over-year. The company reported a net loss and faces liquidity challenges. Analysts expect no revenue growth next year. The turnaround plan progress is slow and uncertain.
The price is about 43% below our fair value near $22, reflecting low growth expectations. The market expects flat revenue growth, which aligns with consensus but may underappreciate execution risks.
Breaks if: cash falls below $190 million over next 4 quarters
Breaks if: adjusted EPS falls below $1.40 in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on returning to growth. The current thesis is intact, supported by recent strong financial results, but faces challenges from elevated risks and mixed management execution.
The market appears to have priced in a justified valuation, with XRAY being seen as cheap compared to its peers. There is a negative expectations gap, indicating that the market may be cautious about future performance.
Fundamentals are likely to remain stable in the near term, as management maintains its sales and earnings outlook despite recent revenue declines. However, the elevated risk level suggests potential volatility in performance.
The thesis hinges on management's ability to execute its Return-to-Growth Action Plan and maintain guidance. Additionally, external factors such as sector performance and economic conditions will play a critical role in shaping outcomes.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the outlook for 2026. However, sales are declining, which challenges the company's growth objectives.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Sustain guidance for 2026 net sales between $3.5B and $3.6B and adjusted EPS between $1.40 and $1.50.
Stated as a priority in 3 of last 3 quarters. Management consistently maintains 2026 net sales guidance between $3.5B and $3.6B and adjusted EPS guidance between $1.40 and $1.50. Actual quarterly revenues show slight decline but management holds outlook steady, indicating a stable but cautious trajectory.
“The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50.”
“We are maintaining our full-year outlook for net sales of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.”
“FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50.”
Breaks if: annual revenue falls below $3.5 billion in FY26
Focus on strengthening distributor relationships, realigning sales teams, and reinvesting in the business to drive sustained, profitable growth.
Stated as a priority in 3 of last 3 quarters. Revenue declined from $961M in 2025-Q4 to $898M in 2026-Q2, while net income improved from a loss of $10M in 2026-Q1 to a gain of $37M in 2026-Q2. Management emphasizes progress on distributor relationships, sales realignment, and reinvestment, indicating delivering momentum but with revenue pressure.
“We execute our Return-to-Growth Action Plan, strengthening and expanding distributor relationships, realigning sales teams, and reinvesting in the business.”
“We are executing our Return-to-Growth Action Plan as expected, advancing commercial restructuring and portfolio innovation.”
“In 2026, we are acting with urgency and accountability on our Return-to-Growth Action Plan to enhance customer experience and commercial performance.”
Sustain guidance for 2026 net sales between $3.5B and $3.6B and adjusted EPS between $1.40 and $1.50.
Stated as a priority in 3 of last 3 quarters. Management consistently maintains 2026 net sales guidance between $3.5B and $3.6B and adjusted EPS guidance between $1.40 and $1.50. Actual quarterly revenues show slight decline but management holds outlook steady, indicating a stable but cautious trajectory.
In the 1 to 3 year view, XRAY's performance will depend on effective management execution and external market conditions. Not investment advice.
“The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50.”
“We are maintaining our full-year outlook for net sales of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.”
“FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50.”